R
Rebecca A. Wright
Researcher at Eli Lilly and Company
Publications - 54
Citations - 4005
Rebecca A. Wright is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Metabotropic glutamate receptor & Metabotropic receptor. The author has an hindex of 31, co-authored 54 publications receiving 3851 citations.
Papers
More filters
Journal ArticleDOI
Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties.
James A. Monn,Matthew John Valli,Steven March Massey,Rebecca A. Wright,Craig R. Salhoff,Bryan G. Johnson,Trevor J. Howe,Charles A. Alt,Rhodes Gary Anthony,Roger L. Robey,Kelly R. Griffey,Joseph P. Tizzano,Mary Jeanne Kallman,David R. Helton,Darryle D. Schoepp +14 more
TL;DR: In this paper, the authors showed that 9 would closely approximate the bioactive conformation of glutamate when acting at group 2 metabotropic glutamate receptors (mGluRs) in the rat cerebral cortical slice.
Journal ArticleDOI
LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors.
A.E. Kingston,Paul L. Ornstein,Rebecca A. Wright,Bryan G. Johnson,Nancy Gail Mayne,J.P. Burnett,Rama M. Belagaje,Su Wu,D D Schoepp +8 more
TL;DR: The in vitro pharmacology of a structurally novel compound, LY341495, was investigated at human recombinant metabotropic glutamate (mGlu) receptor subtypes expressed in non-neuronal cells and represents a novel pharmacological agent for elucidating the function of mGlu receptors in experimental systems.
Journal ArticleDOI
Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.
James A. Monn,Matthew John Valli,Steven Marc Massey,Marvin M. Hansen,Kress Thomas Joseph,James P. Wepsiec,Harkness Allen Robert,John L. Grutsch,Rebecca A. Wright,Bryan G. Johnson,Sherri L. Andis,Ann E. Kingston,Rosemarie Tomlinson,Richard A. Lewis,Kelly R. Griffey,Joseph P. Tizzano,Darryle D. Schoepp +16 more
TL;DR: Evaluation of the functional effects of (-)-9 and (-)-10 on second-messenger responses in nonneuronal cells expressing human mGlu receptor subtypes demonstrated each to be a highly potent agonist for group II mGLU receptors.
Journal Article
Physiological Antagonism between 5-Hydroxytryptamine2A and Group II Metabotropic Glutamate Receptors in Prefrontal Cortex
TL;DR: A close coupling between mGlu2/3 and 5-HT(2A) receptors in the prefrontal cortex that may be relevant for novel therapeutic approaches in the treatment of neuropsychiatric syndromes such as depression and schizophrenia is suggested.
Journal ArticleDOI
LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors.
Darryle D. Schoepp,Bryan G. Johnson,Rebecca A. Wright,Craig R. Salhoff,Nancy Gail Mayne,Su Wu,S.L. Cockerham,J. Paul Burnett,Ramamoorthy Belegaje,David Bleakman,James A. Monn +10 more
TL;DR: LY354740 is a highly potent, efficacious and selective group II (mGlu2/3) receptor agonist, useful to explore the functions of these receptors in situ.